Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders by Diane Nugent (14796787)

“…Without disorder-appropriate treatment, affected individuals potentially face life-threatening bleeding, delayed diagnosis, suboptimal management of invasive procedures, psychosocial distress, pain, and decreased quality-of-life.</p> <p>The National Hemophilia Foundation (NHF) and the American Thrombosis and Hemostasis Network identified the priorities of people with inherited BDs and their caregivers, through extensive inclusive community consultations, to inform a blueprint for future decades of research. …”

Figure S6 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib by Lei Zhu (14951404)

Figure S5 from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib by Lei Zhu (14951404)

Supplementary Table S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution by Iros Barozzi (15113515)

Figure 7 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer by Nami Yamashita (15100557)

“…<p>MUC1 and PBRM1 associate with decreases in responsiveness of TNBC tumors to chemotherapy. …”

Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors by Sandra Ortiz-Cuaran (320342)

DataSheet1_Case report: A case of Rabson–Mendenhall syndrome: long-term follow-up and therapeutic management with empagliflozin.docx by R. Foglino (18870559)

“…<p>Background: Rabson–Mendenhall syndrome (RMS), a rare disorder characterized by severe insulin resistance due to biallelic loss-of-function variants of the insulin receptor gene (INSR), presents therapeutic challenges (OMIM: 262190). …”

Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin by Robert Chen (347308)

Supplementary figures and tables from Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–p... by Chrysiis Michaloglou (403009)

“…<p>Supplementary Figure S1. Vistusertib (AZD2014) causes a decrease in RB phosphorylation in the absence of cell cycle arrest. …”

Figure 7 from Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression by Denis Ohlstrom (15030192)

“…<p>Relapse and disease progression associated with dysregulated apoptosis and increasing drug resistance. <b>A,</b> Volcano plot showing the differential gene expression between LCE-multiple myeloma (MM) cells at timepoint 1 (diagnosis) and LCE-MM cells at timepoint 2 (first relapse, with 1,042 genes higher in LCE-MM at diagnosis, 281 genes higher at first relapse, indicated by green dots for l₂FC > 0.25, <i>P</i> < 0.05). …”

Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research by Shinji Maeda (445222)

Future research directions. by Martha R. Smith (20410184)

Subjects:

Figures 1-3 from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity by Hayley M. Sabol (14951224)

Supplementary Figure S1 - S7 from Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells by Fiona Simpkins (14986536)

SEC demonstrates that the monomeric population of fALS variants is decreased by <i>S</i>-XL6 treatment and that this is associated with reduced aggregation. by Md Amin Hossain (10170815)

Subjects:

Parvalbumin-positive interneurons (PV-INs) in perilesional tissue respond to optogenetic stimulation and are involved in voluntary movement, but show a decreased firing rate. by Livia Vignozzi (22430567)

S1 Data - by Jingxuan Wang (435196)

Subjects:

FIGURE 3 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers by Taraswi Mitra Ghosh (16616796)

“…<p>Metronomic topotecan in combination with DTX showed potency against prostate cancer subtypes, AR^Low/mCRPC/NEPC (PC-3, PC-3M, DU145) and AR^Low/mCSPC/NEPC^{taxane resistant} (DUTXR) cells. Cytotoxicity: <i>In vitro</i> effect of metronomic and conventional administration of topotecan on prostate cancer cell lines was assessed. …”

Supplementary Figure 7 from Metronomic administration of topotecan alone and in combination with docetaxel inhibits epithelial-mesenchymal transition in aggressive variant prostate... by TARASWI MITRA GHOSH (16461350)

Supplementary Figure 7 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate... by Taraswi Mitra Ghosh (16616796)